Acepodia’s allogeneic γδ2 T-cell therapy for EGFR-expressing solid tumors cleared to enter clinic
Feb. 5, 2024
Acepodia Inc. has obtained FDA clearance of its IND application for ACE-2016, an allogeneic γδ2 T-cell therapy for the treatment of epidermal growth factor receptor (EGFR)-expressing malignancies in patients with solid tumors.
